---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-265510"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2021-09-03T23:59:59+00:00"
generated_at: "2026-06-29T05:54:07.930482+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences Q2 revenue $30.4M (+59% YoY); operating income turns positive at $3.8M

## Summary
- Revenue $30.4M, +59% YoY; gross margin improved to 65% from 43%.
- Operating income $3.8M vs. ($0.2M) a year ago; net income $2.7M down from $8.1M.
- Installed base reached 855 instruments, with 104 placements in Q2.
- Launched Aurora Cell Sorter and Automated Sample Loader during the quarter.
- Completed IPO in July 2021, raising $215M in net proceeds to strengthen balance sheet.

## SEC filing metadata
- accession: 0001193125-21-265510
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2021-09-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312521265510/0001193125-21-265510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312521265510/d187138d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-265510
- JSON: https://secwatch.observer/filing/0001193125-21-265510.json
- Plain text: https://secwatch.observer/filing/0001193125-21-265510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.